Paxlovid didn't prevent long COVID in a randomized trial. Now what?
Long COVID research had a big week — and not all the news was good.
A high-profile Norwegian trial just tested one of the most promising prevention strategies and came up short.
Paxlovid vs. Long COVID: The Randomized Trial Results Are In 💊
- The PANORAMIC Norway trial was a double-blind, placebo-controlled study testing whether nirmatrelvir-ritonavir (Paxlovid) during acute COVID-19 infection could prevent long COVID — specifically the fatigue, cognitive problems, and breathlessness that linger for months.
- Cohort studies had suggested antivirals might cut long COVID risk, which made this prospective test the one researchers were waiting for.
- The trial's results did not confirm that benefit — meaning the antiviral-prevents-long-COVID hypothesis, at least for this drug in this design, didn't hold up under controlled conditions.
Why it matters: This was the cleanest test yet of a plausible, already-available intervention. The signal that looked real in observational data faded when randomization removed the confounders. That's a meaningful reset for the prevention conversation.
Key Findings
A Simpler Test for Post-Exertional Crash May Actually Work 🏃
- The two-day cardiopulmonary exercise test is the gold standard for objectively measuring post-exertional malaise in long COVID — but it's expensive and hard on patients.
- Researchers tested a two-day 6-minute incremental step test using wireless wearable sensors as a more accessible alternative, finding it showed agreement and reliability with the gold standard.
Women's Brains Bear a Hidden Scar From COVID Inflammation 🧠
- In 60 previously hospitalized COVID-19 survivors scanned three months after recovery, higher acute inflammatory burden predicted diffuse white matter damage in women — but not in men, despite similar inflammation levels during illness.
- In female survivors, that white matter damage was linked to slower psychomotor coordination, and the brain imaging measure fully accounted for the connection between inflammation and cognitive slowdown.
Kids With Long COVID Are Struggling in School, Not Just Clinically 📚
- Across 21 U.S. children's hospitals, children with clinician-confirmed long COVID had 3.5 times higher odds of school decline and 4.6 times higher odds of new or worsening mental health symptoms compared to COVID-infected kids without long COVID.
- The study, covering March 2020 through December 2022, is a reminder that functional impairment — not just symptom lists — needs to be part of pediatric long COVID evaluations.
An Anti-Inflammatory Diet Is Linked to Lower Long COVID Risk 🥗
- In a prospective cohort of over 69,000 UK Biobank participants, higher scores on two dietary inflammatory indices — the Dietary Inflammatory Index and the Empirical Dietary Inflammatory Pattern — were associated with increased risk of developing long COVID.
- The finding is observational, but it fits the biological logic: diet modulates systemic inflammation, and inflammation is a core long COVID mechanism.
Blood Biomarkers Flag Brain Damage After Severe COVID 🩸
- In a case-control study of 325 participants in Thailand, those who had severe or critical COVID-19 showed significantly higher levels of neurofilament light chain, GFAP, and phosphorylated tau181 — proteins associated with neuronal injury and neurodegeneration — compared to mild cases and asymptomatic COVID survivors.
- Critically ill patients also showed stronger correlations between these brain injury markers and pro-inflammatory proteins, suggesting the two processes are linked in the most severe cases.
Long COVID Patients Built Their Own Knowledge System — and It Worked 🐦
- An analysis of 2.8 million #LongCOVID tweets found that patients collectively named and legitimized their condition on Twitter in May 2020 — months before formal medical recognition — forming a structured epistemic community organized around knowledge-sharing rather than policy fights.
- Long COVID achieved WHO recognition within months, a timeline that contrasts sharply with the decades-long recognition struggles of similar chronic conditions.
Implications
The Paxlovid trial failure sharpens an uncomfortable question: if the most available antiviral doesn't prevent long COVID under controlled conditions, what does? Biomarker and dietary data point toward inflammation as a key driver — but whether intervening on inflammation during or after acute infection actually changes long-term outcomes remains untested.
Studies in this issue
Primary sources used for this newsletter.
- Nirmatrelvir for treating early COVID-19 to reduce long COVID risk in Norway: a double-blind, placebo-controlled trialmain storyThe Lancet. Infectious diseases2026-07-16PMID 42462744
- How Inflammation During Acute COVID-19 Relates to Lasting White Matter Damage and Thinking Abilities Differently in Men and Womenkey findingBiology2026-07-15PMID 42450602
- Links between diet-related inflammation and the risk of Long COVID in a follow-up studykey findingBMC public health2026-07-15PMID 42458333
- Comparing a two-day 6-minute step test and exercise test for measuring post-exertion tiredness in long COVIDkey findingPloS one2026-07-14PMID 42447127
- How COVID-19 infection affects children's daily functioning based on health recordskey findingJournal of pediatric rehabilitation medicine2026-07-14PMID 42444121
- Blood markers of inflammation and brain injury vary with COVID-19 severity in people with lasting neurological symptomskey findingInternational journal of immunopathology and pharmacology2026-07-16PMID 42460883
- How Long COVID Patients Create Online Knowledge Networks and Face Injusticekey findingSocial science & medicine (1982)2026-07-16PMID 42462688
Continue reading
All Long Covid issuesGet the next Long Covid issue
Seven papers, once a week. Free.